The authors recommend digoxin for heart failure patients with persistent dyspnea despite mortality-reducing therapy, based on Na,K-ATPase pump dynamics.
No takes yet. Share an insight, caveat, or question.
Does not support changing digoxin use in heart failure; leaves open Na,K-ATPase modulation as a target for randomized trials.
Kjeldsen et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: